自身免疫性甲状腺疾病钠/碘同向转运体的相关性研究

摘要

Objective To investigate the correlation of sodium/iodide symporter antibody (NISAb) with the content of TgAb and TPOAb among different autoimmune thyroid disease (AITD), and observe the changes of NISAb of the patients with hyperthyroidism before and after drug treatment. Methods 40 patients with Gravesˊ disease (GD), 40 with hashimoto low thyroid function (HT) and 40 healthy normal controls (NC) were selected. Venous blood of the patients was collected. The content of NISAb was detected by ELISA method, while the content of TgAb and TPOAb were detected by electrochemical luminescence method. And the correlation of the content of NISAb with that of TgAb and TPOAb was compared. The content of NISAb in 20 cases with GD before and after the medication was analyzed. Results (1) The correlation coefficient R between NISAb and TgAb, TPOAb content was respectively 0.90 and 0.85 in patients with hyperthyroidism (both P<0.05). NISAb and TgAb, TPOAb was positively linear correlated in patients with GD. The correlation coefficient R between NISAb and TgAb, TPOAb content was respectively -0.64 and -0.52 in patients with hashimoto low thyroid function (both P<0.05). NISAb and TgAb, TPOAb was negatively linear correlated in patients with hashimoto low thyroid function. The P value between NISAb, TgAb and TPOAb content was respectively 0.63 and 0.22 (both P>0.05) in the normal controls by correlation analysis. There was no linear correlation between them. (2) The content of NISAb in patients with GD was higher than that in the normal healthy population by t test (P<0.05). The content of NISAb in patients with HT was lower than that in the normal healthy population by t test (P<0.05). (3) There were statistically significant differences of NISAb content before and after treatment in patients with hyperthyroidism by t test (P<0.05). Conclusion (1) The content of plasma NISAb and TgAb, TPOAb content are relevant between patients with GD and HT patients. The content of plasma NISAb is positively correlated with that of TgAb and TPOAb in patients with GD, while the content of plasma NISAb is negatively correlated with that of TgAb and TPOAb in patients with HT. (2) The content of plasma NISAb in patients with GD is higher than that in the normal healthy population, and the content of NISAb in HT patients is lower than that in the healthy population. (3) The content of NISAb has obviously decreased in patients with GD after treatment, and the difference is obvious.%目的：研究不同自身免疫性甲状腺疾病（AITD)钠/碘同向转运体抗体（NISAb)与甲状腺球蛋白抗体（TgAb),甲状腺过氧化物酶抗体（TPOAb)含量之间的相关性，并观察甲亢患者药物治疗前后NISAb含量的变化。方法选择甲亢（GD)患者，桥本甲状腺功能低下者（HT),健康正常人组（NC)各40例，检测NISAb、TgAb、TPOAb含量，比较NISAb含量与TgAb、TPOAb含量之间的相关性，并分析20例甲亢患者药物治疗前后NISAb含量的差异。结果（1)甲亢患者NISAb与TgAb、TPOAb含量,相关系数R分别为0.90、0.85， P均<0.05,呈直线相关性，GD患者 NISAb与TgAb，TPOAb呈正相关，HT患者NISAb与TgAb、TPOAb含量,相关系数r分别为-0.64、-0.52，P均<0.05,呈线性负相关性。正常人群NISAb, TgAb，TPOAb含量之间,相关性分析，P值分别为0.63、0.22，P均>0.05,无线性相关性。（2)甲亢患者NISAb含量与正常人群对比分析，t检验， P<0.05, NISAb含量高于正常人群。HT患者NISAb含量与正常人群对比分析，t检验， P<0.05，NISAb含量低于正常人群。（3)甲亢患者治疗前后NISAb含量对比分析，t检验，P<0.05差异有统计学意义。结论（1)GD和HT患者血浆NISAb含量与TgAb, TPOAb 含量之间具有相关性,GD患者血浆NISAb含量与TgAb,TPOAb含量之间呈正相关，HT患者血浆NISAb含量与TgAb,TPOAb含量之间呈负相关。（2) GD患者血浆NISAb含量高于健康人群，HT患者NISAb含量低于健康人群。（3) GD患者治疗后NISAb含量明显降低，差异明显。